Evidence map›Paper›PMID 38914844›Full record

ArticleCell research2024

Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: clinical benefit in patients with advanced solid tumors.

Xinjing Wang, Wei Wang, Siyi Zou, Zhiwei Xu, Dan Cao, Shuai Zhang, Minzhi Wei, Qian Zhan, Chenlei Wen, Fanlu Li and 5 more

Registry-linked trialAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07004244 (Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07004244 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

Safety and Efficacy of KRAS Vaccine in the Treatment of KRAS-mutant Malignancies

TypeinterventionalSponsorSichuan UniversityRan2025 to 2027Enrolled20ConditionsMalignant TumorsArmsKRAS-mutated mRNA vaccine, TORIPALIMAB, Pemetrexed+carboplatin
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xinjing Wang *Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wei Wang *Shanghai Xinpu BioTechnology Company Limited, Shanghai, China.
Siyi Zou *Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiwei Xu *Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dan CaoHongene Biotech Corporation, Shanghai, China.
Shuai ZhangShanghai Xinpu BioTechnology Company Limited, Shanghai, China.
Minzhi WeiHongene Biotech Corporation, Shanghai, China.
Qian ZhanDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chenlei WenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fanlu LiDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hao ChenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Da FuDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. fuda@shsmu.edu.cn.
Lingxi JiangDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jlx12120@rjh.com.cn.
Ming ZhaoShanghai Xinpu BioTechnology Company Limited, Shanghai, China. zhaoming@xinpuoncology.com.
Baiyong ShenDepartment of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. shenby@shsmu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82073326National Natural Science Foundation of China (National Science Foundation of China) 82200277
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedNeoplasmsProto-Oncogene Proteins p21(ras)Cancer VaccinesCombined Modality TherapyFemaleHumansMaleMiddle AgedmRNA VaccinesAntibodies, Monoclonal, HumanizedCancer VaccinesKRAS protein, humanmRNA VaccinespembrolizumabProto-Oncogene Proteins p21(ras)

Identifiers

PMID38914844
PMCPMC11369195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.